Preclinical Efficacy of the C-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-animal PET

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2007 Dec 14

PMID 18077531

Citations 25

Authors

Jeffrey R Tseng

Keon Wook Kang

Mangal Dandekar

Shahriar Yaghoubi

Joseph H Lee

James G Christensen

Stephen Muir

Patrick W Vincent

Neil R Michaud

Sanjiv S Gambhir

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using (18)F-FDG small-animal PET.

Methods: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using (18)F-FDG small-animal PET and compared with tumor volume growth curves.

Results: The maximum %ID/g (percentage injected dose per gram of tissue) of (18)F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of (18)F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment.

Conclusion: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of (18)F-FDG PET to assess early tumor response for CE-355621.

Citing Articles

Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography.

Floresta G, Abbate V Med Res Rev. 2022; 42(4):1588-1606.

PMID: 35292998 PMC: 9314990. DOI: 10.1002/med.21885.

Docetaxel and Lidocaine Co-Loaded (NLC-in-Hydrogel) Hybrid System Designed for the Treatment of Melanoma.

de Moura L, Ribeiro L, de Carvalho F, Rodrigues da Silva G, Lima Fernandes P, Brunetto S Pharmaceutics. 2021; 13(10).

PMID: 34683846 PMC: 8537790. DOI: 10.3390/pharmaceutics13101552.

The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.

Aftimos P, Rolfo C, Rottey S, Barthelemy P, Borg C, Park K Biomedicines. 2021; 9(6).

PMID: 34200749 PMC: 8229762. DOI: 10.3390/biomedicines9060665.

Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

Tarpley M, Oladapo H, Strepay D, Caligan T, Chdid L, Shehata H Eur J Pharm Sci. 2021; 162:105821.

PMID: 33781856 PMC: 8404221. DOI: 10.1016/j.ejps.2021.105821.

Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.

Zhang Y, Jain R, Zhu M Biomedicines. 2017; 3(1):149-181.

PMID: 28536405 PMC: 5344234. DOI: 10.3390/biomedicines3010149.

References

Jerusalem G, Hustinx R, Beguin Y, Fillet G . Evaluation of therapy for lymphoma. Semin Nucl Med. 2005; 35(3):186-96. DOI: 10.1053/j.semnuclmed.2005.02.004. View

Parulekar W, Eisenhauer E . Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst. 2004; 96(13):990-7. DOI: 10.1093/jnci/djh182. View

Ponten J, MACINTYRE E . Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand. 1968; 74(4):465-86. DOI: 10.1111/j.1699-0463.1968.tb03502.x. View

Oyama N, Kim J, Jones L, Mercer N, Engelbach J, Sharp T . MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol. 2002; 29(8):783-90. DOI: 10.1016/s0969-8051(02)00346-3. View

Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J . 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003; 39(14):2012-20. DOI: 10.1016/s0959-8049(03)00073-x. View

van Waarde A, Cobben D, Suurmeijer A, Maas B, Vaalburg W, de Vries E . Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004; 45(4):695-700. View

Barthel H, Cleij M, Collingridge D, Hutchinson O, Osman S, He Q . 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003; 63(13):3791-8. View

Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A . Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging. 2003; 30(5):737-47. DOI: 10.1007/s00259-002-1052-6. View

Hudson H, Larkin R . Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994; 13(4):601-9. DOI: 10.1109/42.363108. View

10.

Fueger B, Czernin J, Hildebrandt I, Tran C, Halpern B, Stout D . Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006; 47(6):999-1006. View

11.

Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

12.

Wahl R, HENRY C, Ethier S . Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992; 183(3):643-7. DOI: 10.1148/radiology.183.3.1584912. View

13.

Goerres G, Stupp R, Barghouth G, Hany T, Pestalozzi B, Dizendorf E . The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005; 32(2):153-62. PMC: 2706372. DOI: 10.1007/s00259-004-1633-7. View

14.

Su H, Bodenstein C, Dumont R, Seimbille Y, Dubinett S, Phelps M . Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006; 12(19):5659-67. DOI: 10.1158/1078-0432.CCR-06-0368. View

15.

Hoffman E, Huang S, Phelps M . Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr. 1979; 3(3):299-308. DOI: 10.1097/00004728-197906000-00001. View

16.

Becher O, Holland E . Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 2006; 66(7):3355-8, discussion 3358-9. DOI: 10.1158/0008-5472.CAN-05-3827. View

17.

Cullinane C, Dorow D, Kansara M, Conus N, Binns D, Hicks R . An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res. 2005; 65(21):9633-6. DOI: 10.1158/0008-5472.CAN-05-2285. View

18.

Leyton J, Latigo J, Perumal M, Dhaliwal H, He Q, Aboagye E . Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005; 65(10):4202-10. DOI: 10.1158/0008-5472.CAN-04-4008. View

19.

Guerin C, Luddy C, Abounader R, Lal B, Laterra J . Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. Biochem Biophys Res Commun. 2000; 273(1):287-93. DOI: 10.1006/bbrc.2000.2935. View

20.

Tseng J, Dandekar M, Subbarayan M, Cheng Z, Park J, Louie S . Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med. 2005; 46(11):1851-7. PMC: 4154806. View